These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 35312753

  • 1. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy.
    Lee S, Shroff RT, Makawita S, Xiao L, Danner De Armas A, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, Wolff RA, Javle M.
    Clin Cancer Res; 2022 Jun 01; 28(11):2229-2236. PubMed ID: 35312753
    [Abstract] [Full Text] [Related]

  • 2. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs FT, Ebert MP, Distelrath A, Geissler M, Trojan J, Schütz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger MM, Lindig U, Duerr EM, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser AK, Schadmand-Fischer S, Galle PR, Woerns M, Working Group of Internal Oncology.
    Eur J Cancer; 2014 Dec 01; 50(18):3125-35. PubMed ID: 25446376
    [Abstract] [Full Text] [Related]

  • 3. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 4. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES, Cao B, Kim J, Al-Toubah TE, Mehta R, Centeno BA, Kim RD.
    Cancer; 2021 Apr 15; 127(8):1293-1300. PubMed ID: 33289918
    [Abstract] [Full Text] [Related]

  • 5. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
    Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I.
    Oncologist; 2018 Dec 15; 23(12):1407-e136. PubMed ID: 29853658
    [Abstract] [Full Text] [Related]

  • 6. Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
    Zhou N, Li X, Yang Y, Tan S, Zhang S, Huang Q, Gou H.
    BMC Cancer; 2023 Aug 07; 23(1):729. PubMed ID: 37550655
    [Abstract] [Full Text] [Related]

  • 7. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ.
    BMC Cancer; 2008 Dec 18; 8():374. PubMed ID: 19091129
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.
    Oncologist; 2012 Dec 18; 17(1):13. PubMed ID: 22210086
    [Abstract] [Full Text] [Related]

  • 9. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A, Gramaticu I, Dinu I, Gheorghe L, Alexandrescu S, Buica F, Luca I, Becheanu G, Herlea V, Simionov I, Hrehoret D, Lupescu I, Popescu I, Diculescu M.
    J Gastrointestin Liver Dis; 2012 Sep 18; 21(3):277-84. PubMed ID: 23012669
    [Abstract] [Full Text] [Related]

  • 10. Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study.
    Lim SH, Hong JY, Park JO, Park YS, Kim ST.
    Anticancer Res; 2023 Sep 18; 43(9):4161-4167. PubMed ID: 37648323
    [Abstract] [Full Text] [Related]

  • 11. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, Munshi HG, Benson AB, O'Dwyer PJ.
    JAMA Oncol; 2018 Dec 01; 4(12):1707-1712. PubMed ID: 30178032
    [Abstract] [Full Text] [Related]

  • 12. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
    Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q, Zhu F, Li X, Qian X, Hu J, Zhao F, Mao W, Sun J, Wang J, Han G, Li C, Xia Y, Seesaha PK, Zhu D, Li H, Zhang J, Wang G, Wang X, Li X, Shu Y.
    J Immunother Cancer; 2020 Nov 01; 8(2):. PubMed ID: 33172881
    [Abstract] [Full Text] [Related]

  • 13. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S, Shimizu K, Okamoto T, Toki M, Suzuki Y, Okano N, Naruge D, Kawai K, Kobayashi T, Kasuga A, Kitamura H, Takasu A, Nagashima F, Sugiyama M, Furuse J.
    Anticancer Res; 2017 Feb 01; 37(2):909-914. PubMed ID: 28179351
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
    Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J, Okusaka T.
    Ann Oncol; 2014 Feb 01; 25(2):391-8. PubMed ID: 24351397
    [Abstract] [Full Text] [Related]

  • 15. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA, Kemeny NE, Jarnagin WR.
    JAMA Oncol; 2020 Jan 01; 6(1):60-67. PubMed ID: 31670750
    [Abstract] [Full Text] [Related]

  • 16. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C, Li Y, Yang C, Qiao L, Tang L, Zheng Y, Chen X, Qian Y, Yang J, Wu D, Xie F.
    Front Immunol; 2022 Jan 01; 13():946861. PubMed ID: 35967452
    [Abstract] [Full Text] [Related]

  • 17. Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
    Okano N, Furuse J, Ueno M, Morizane C, Yamanaka T, Ojima H, Ozaka M, Sasaki M, Takahara N, Nakai Y, Kobayashi S, Morimoto M, Hosoi H, Maeno S, Nagashima F, Ikeda M, Okusaka T.
    Oncologist; 2021 Feb 01; 26(2):97-e201. PubMed ID: 33010112
    [Abstract] [Full Text] [Related]

  • 18. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF, BINGO investigators.
    Lancet Oncol; 2014 Jul 01; 15(8):819-28. PubMed ID: 24852116
    [Abstract] [Full Text] [Related]

  • 19. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J, Gaspersz MP, Belkouz A, van Vugt JLA, Coelen RJS, de Groot JWB, Ten Tije AJ, Meijer WG, Pruijt JFM, van Voorthuizen T, van Spronsen DJ, Rentinck M, Ten Oever D, Smit JM, Otten HM, van Gulik TM, Wilmink JW, Groot Koerkamp B, Klümpen H.
    Acta Oncol; 2018 Jun 01; 57(6):807-812. PubMed ID: 29265948
    [Abstract] [Full Text] [Related]

  • 20. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
    Demols A, Borbath I, Van den Eynde M, Houbiers G, Peeters M, Marechal R, Delaunoit T, Goemine JC, Laurent S, Holbrechts S, Paesmans M, Van Laethem JL.
    Ann Oncol; 2020 Sep 01; 31(9):1169-1177. PubMed ID: 32464280
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.